About: A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19
Creator	Li, Yi Niu, Peihua Tan, Wenjie Huang, Baoying Ye, Fei Ma, Jing Peng, Feng Tan, Xin Xie, Jun Tang, Wei Zheng, Fang Zhou, Ning Xu, Yun Xie, Yuanlin Zhou, Zhiguo Zuo, Qi Cai, Chunlin Gong, Guozhong Huang, Yaxiong Jiang, Yongfang Wang, Wenlong Xiao, Xinqiang Zhou, Yanwen Zhou, Zhiguang
Source	MedRxiv
abstract	Abstract Background Novaferon, a novel protein drug approved for the treatment of chronic hepatitis B in China, exhibits potent antiviral activities. We aimed to determine the anti-SARS-CoV-2 effects of Novaferon in vitro, and conducted a randomized, open-label, parallel group study to explore the antiviral effects of Novaferon for COVID-19. Methods In laboratory, the inhibition of Novaferon on viral replication in cells infected with SARS-CoV-2, and on SARS-CoV-2 entry into healthy cells was determined. Antiviral effects of Novaferon were evaluated in COVID-19 patients with treatment of Novaferon, Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir. The primary endpoint was the SARS-CoV-2 clearance rates on day 6 of treatment, and the secondary endpoint was the time to the SARS-CoV-2 clearance in COVID-19 patients Results Novaferon inhibited the viral replication in infected cells (EC50=1.02 ng/ml), and protected healthy cells from SARS-CoV-2 infection (EC50=0.1 ng/ml). Results from the 89 enrolled COVID-19 patients showed that both Novaferon and Novaferon plus Lopinavir/Ritonavir groups had significantly higher SARS-CoV-2 clearance rates on day 6 than the Lopinavir/Ritonavir group (50.0% vs.24.1%, p = 0.0400, and 60.0% vs.24.1%, p = 0.0053). Median time to SARS-CoV-2 clearance were 6 days, 6 days, and 9 days for three groups respectively, suggesting a 3-dayreduction of time to SARS-CoV-2 clearance in both Novaferon and Novaferon plus Lopinavir/Ritonavir groups compared with Lopinavir/Ritonavir group. Conclusions Novaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justified the further evaluation of Novaferon. Key words: COVID-19, SARS-CoV-2, Novaferon, Antiviral drug, Lopinavir/Ritonavir
has issue date	2020-04-29(xsd:dateTime)
bibo:doi	10.1101/2020.04.24.20077735
has license	medrxiv
sha1sum (hex)	444fd64e3c0b49e1ec687ea7acba268e64870e62
schema:url	https://doi.org/10.1101/2020.04.24.20077735
resource representing a document's title	A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19
resource representing a document's body	covid:444fd64e3c0b49e1ec687ea7acba268e64870e62#body_text
is schema:about of	named entity 'potent' named entity 'protein' named entity 'ACTIVITIES' named entity 'CHRONIC HEPATITIS B' named entity 'COVID-19' named entity 'RANDOMIZED' named entity 'SARS-COV-2' named entity 'antiviral' named entity 'China' named entity 'antiviral' named entity 'antiviral' named entity 'China' named entity 'COVID' named entity 'COVID' named entity 'clinical studies' named entity 'CC-BY-NC-ND 4.0' named entity 'antiviral' named entity 'preprint' named entity 'preventive effect' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'Vero E6' named entity 'preprint' named entity 'COVID' named entity 'COVID-19' named entity 'Lopinavir/Ritonavir' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'sample size' named entity 'virus' named entity 'adverse events' named entity 'SARS-CoV-2' named entity 'sample size' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'treatment groups' named entity 'null hypothesis' named entity 'adverse events' named entity 'RT-PCR' named entity 'statistical test' named entity 'protein' named entity 'medRxiv' named entity 'Lopinavir/Ritonavir' named entity 'coronavirus' named entity 'Vero E6' named entity 'preprint' named entity 'Chinese Pharmacopeia' named entity 'preprint' named entity 'medRxiv' named entity 'Vero E6' named entity 'COVID-19' named entity 'biosafety level-3' named entity 'COVID-19' named entity 'COVID' named entity 'treatment groups' named entity 'viral RNA' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'treatment groups' named entity 'COVID' named entity 'drug administration' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software